Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

Grants

Funding Acknowledgements

YLQ has received support for travel to meetings for the study or other purposes (personal) from MSD and GlaxoSmithKline. GAHS has received an independent grant from MSD for epidemiological study related to genital warts in Colombia; and payments from MSD for travel accommodation at the International HPV conference in Canada, 2011. NM has received payment for board membership (personal) from Merck, and for lectures (personal) from Merck and Sanofi Pasteur. AMN has received payment for board membership (personal) and consultancy (personal) from GlaxoSmithKline, and for lectures (personal) from GlaxoSmithKline and MSD. CJLMM has received payment for board membership (institution) from Qiagen until 2009; payment for consultancy from Qiagen (institution); payment for lectures including service on speakers bureaus (institution) from Roche and GlaxoSmithKline; payment for patents (institution) from Qiagen for HPV detection by gp5+/6+; royalties (institution) from Oncomethylome Sciences for a patent on promoter methylation of Technological Support for Strategy, Learning and Change specific marker for cervical intraepithelial neoplasia 2+2005; and travel, accommodations, or meeting expenses (personal) from Qiagen and Roche. TCW has received payment for consultancy (personal) from Merck, GlaxoSmithKline, GenProbe, and Roche Molecular Diagnostics; and for lectures including service on speakers bureaus (personal) from Merck, GlaxoSmithKline, and Roche Molecular Diagnostics. SDS has received payment for consultancy (personal) from Qiagen, and for lectures including service on speakers bureaus (personal) from Qiagen, Sanofi, and GlaxoSmithKline. LA has received support for travel to meetings for the study or other purposes (institutional) from Sanofi Pasteur MSD. NG has received institutional support for occasional travel by GlaxoSmithKline and Merck. FXB has received payment for consultancy (personal) from MSD Internal Steering Committee; payment for expert testimony (personal) from GlaxoSmithKline Food and Drug Administration and EMEA clinical expert; and grants (institution) from GlaxoSmithKline, MSD, and Sanofi Pasteur MSD for epidemiological studies; payment for development of educational presentations (institution) from GlaxoSmithKline; travel, accommodations, and meeting expenses (personal) from GlaxoSmithKline and Sanofi Pasteur MSD. JB has received a grant (institution) from MSD Israel for a research assistant working with the pathology laboratory staff, assisting in the assembly and transport of paraffin blocks; consultancy (personal) payments from MSD Israel; and payment for lectures, including service on speakers bureaus (personal) from GlaxoSmithKline Israel. GIS has received a study grant (institution) from Marato de TV3 Foundation, and grants (institution) from Merck. XC has received a study grant (institution) from Sanofi Pasteur MSD and Merck; consultancy payments from Sanofi Pasteur MSD, and GlaxoSmithKline; grants (institution) from GlaxoSmithKline, Merck, Sanofi Pasteur MS D; and payment for lectures including service on speakers bureaus (personal) from GlaxoSmithKline and Sanofi Pasteur MSD. BL has received payment for lectures including service on speakers bureaus (personal) from Roche and Qiagen. SAT has received payment for lectures including service on speakers bureaus from MSD; and travel, accommodations, or meeting expenses from Merck.SMG has received board membership from GlaxoSmithKline, Commonwealth Serum Laboratories advisory board for cervical cancer vaccine; payment for development of education presentations from GaxoSmithKline, EXCEL program; grants have been paid to SMG's institute by the Royal Women's Hospital Melbourne. CC has received payment for consultancy from Merck (steering committee about HPV vaccination), expert testimony from Roche, and funding for travel from Sanofi Pasteur, MSD, and GlaxoSmithKline. CLL has received institutional grants from GlaxoSmithKline. The other authors declared no conflicts of interest.The study has been partly supported by Spanish public grants from the Instituto de Salud Carlos III (grants numbers FIS PI030240, FIS PI061246, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, and CIBERESP), Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR 2005SGR 00695 and 2009SGR126), Marato de TV3 Foundation (051530), and GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, and Merck. The contribution of Cristina Rajo in the preparation of the report is recognised.